ISPOR 21ST ANNUAL INTERNATIONAL MEETING ISSUE PANEL CONSIDERS MCDA AS A POSSIBLE NEW PARADIGM IN HEALTH CARE DECISION MAKING

Published May 24, 2016
Washington, DC—May 24, 2016—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting Issue Panel 12—Multi-Criteria Decision Analysis: A New Paradigm in Health Care Decision Making? What Are the Current Status, Challenges, and Opportunities?—was held this afternoon in Washington, DC, USA. The Issue Panel moderator was James Dolan, MD, Professor, University of Rochester, Rochester, NY, USA. Panelists included:
  • Kevin Marsh, PhD, Executive Director, Evidera, London, UK
  • Mireille M. Goetghebeur, PhD, MEng, Global Scientist, LASER Analytica and School of Public Health, University of Montreal, Montreal, QC, Canada
  • Mabel Moreno Viscaya, PhD, Senior Economist, Instituto de Evaluación Tecnológica en Salud (IETS), Bogata, Colombia
Multiple criteria decision analysis (MCDA), an application of decision analytics that can help improve the quality of complicated decisions, is gaining significant interest in health care. MCDA application in health care decision making can also be subject to controversy. For example, while many MCDA methods are available, little guidance currently exists for how to choose the right technique for a particular problem. The ISPOR Multi-Criteria Decision Analysis in Health Care Decision Making Emerging Good Practices Task Force was established in 2014 to help fill this knowledge gap. The panel used content from a two-day workshop that convened MCDA experts from around the world to illustrate and spark discussion of the controversies and complexities of health care decisions. The panelists encouraged attendees to apply MCDA in health economics and outcomes research to provide a way to change the current paradigm in health care decision making. Additional information and resources on MCDA can be found on the ISPOR website, including: Presentations and slide decks from the ISPOR 21st Annual International meeting can be found here. Interested parties can follow news and developments from the meeting on social media using the hashtag #ISPORDC.

###

Related Stories

ISPOR Announces 2025 Health Economics and Outcomes Research Award Honorees

Oct 20, 2025

ISPOR announced the recipients of its 2025 Health Economics and Outcomes Research (HEOR) Scientific and Leadership Awards. ISPOR Scientific Awards are designed to foster and recognize excellence and outstanding achievement in HEOR and its Leadership Awards recognize excellence and outstanding leadership in the field.

The Ozempic Paradox: How Spending Billions on Weight-Loss Drug Would Actually Reduce Overall Medicare Costs

Oct 14, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a landmark study by researchers at the University of Washington, Curta, Inc, and the University of North Carolina showing that broad Medicare coverage of semaglutide in diabetes, obesity, and liver disease could generate significant cost savings while delivering substantial health benefits to beneficiaries. The report, “Comprehensive Access to Semaglutide: Clinical and Economic Implications for Medicare,” was published in the October 2025 issue of Value in Health.

ISPOR Europe 2025 Plenaries and Speakers Announced

Oct 13, 2025

ISPOR announced details for its ISPOR Europe 2025. The conference is the leading global conference in Europe for health economics and outcomes research (HEOR) and is scheduled for 9-12 November in Glasglow, Scotland, UK with the theme, “Powering Value and Access Through Patient-Centered Collaboration.”
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×